Insights

The UK government has announced that several Patent Cooperation Treaty (PCT) fees applicable through the UK Intellectual Property Office (UK IPO) will change from 1 April 2026. Under the published schedule, the transmittal fee will be £100, the search fee £1,632, the international filing fee £1,242 for the first 30 pages, with an additional £14 for each page over 30, and the fee for restoration of priority will be £200. Reductions remain available for qualifying electronic filings.

On its face, this is a routine fee update. In practice, however, the announcement matters for much more than headline numbers. It affects how applicants time international filings around quarter-end, how they manage specification length and document format, and how they prepare for procedural contingencies such as late priority-related decisions. For businesses using the UK route as part of their international patent filing strategy, the real issue is not only cost inflation but how filing discipline and digital workflow can now make a more measurable difference.

According to recent reporting by Asia IP, and as confirmed by official information released by the relevant authorities, from March 1, 2026, PCT applicants filing through IP Australia may designate the European Patent Office (EPO) or the Intellectual Property Office of Singapore (IPOS) as their International Searching Authority (ISA) and International Preliminary Examining Authority (IPEA), in addition to the previously available options of IP Australia and the Korean authority. For applicants using Australia as the receiving Office, this is more than a procedural update. It materially changes how international filing strategy can be aligned with downstream market priorities.

The practical significance of the new options lies in what each authority may signal for later prosecution. The EPO route is especially attractive for applicants expecting to enter Europe, because where the EPO carries out the international search and also acts for Chapter II examination, the applicant may obtain a 75 percent reduction in the European examination fee at regional phase entry. By contrast, the IPOS option is likely to appeal to applicants who want stronger visibility over Chinese-language prior art at an earlier stage, particularly where R&D, manufacturing, supply chains or future enforcement concerns are closely tied to Asia.

The U.S. Patent and Trademark Office’s final rule published in the Federal Register on March 20, 2026 will take effect on July 20, 2026 and will require foreign applicants, inventors, and patent owners whose domicile is outside the United States or its territories to be represented in patent matters by a USPTO-registered patent practitioner. In the agency’s own framing, the change is meant to improve filing quality, curb fraud and other false submissions, and align U.S. practice more closely with the approach already taken by many foreign intellectual property offices.

The practical significance goes well beyond a simple instruction to “hire local counsel.” For cross-border filers, the rule is likely to affect who may validly sign and submit application data sheets, micro entity certifications, petitions, corrections, responses, and certain post-grant papers. That shifts the issue from a matter of procedural convenience to a threshold filing condition in many situations. Companies that still rely on fragmented cross-border filing workflows should therefore read this as a near-term operational deadline, not as a background compliance tweak that can be addressed later.

According to practice updates reported by JD Supra in February 2026 and echoed by Womble Bond Dickinson in March 2026, the China National Intellectual Property Administration (CNIPA) appears to have changed how it serves certain notifications in Madrid designations to China. Rather than forwarding those notifications to the local Chinese trademark agent, CNIPA is said to be sending them directly to the representative recorded with WIPO, or in some cases to the holder itself. If this practice continues, many brand owners will need to rethink the assumption that their China agent will automatically receive and action every contentious notice.

The operational significance is immediate. In non-use cancellation, opposition, invalidation and similar proceedings, missing the first notice can quickly compress the time available for evidence collection, instructions and local filing. If the local China agent is no longer copied by default, applicants and portfolio managers may need to monitor paper mail sent to the WIPO-recorded address much more closely and preserve the envelope itself, because the date of postal receipt may become critical to calculating response deadlines.

An article by CNIPA Commissioner Shen Changyu published in the 2026 Issue 6 of Qiushi puts a hard number on one of China’s longest-running innovation problems: more than 1.349 million existing patents held by universities and research institutions had not been effectively commercialized before a nationwide stocktaking and value assessment was carried out across more than 2,700 institutions. The article also sets that backlog against two powerful indicators of economic relevance. Patent-related technology contract turnover reached RMB 1.18 trillion in 2025, while the value added of China’s patent-intensive industries reached RMB 18.04 trillion in 2024, accounting for 13.38% of GDP.

The real significance of those figures is not simply that China has “many patents,” but that the next phase of IP policy is being forced to confront a more difficult question: which patents can actually move into products, supply chains, licensing programs and industrial investment. Shen identifies five recurring obstacles—patents that cannot be commercialized, are not worth commercializing, are too risky to commercialize, lack capable intermediaries, or face weak market conditions. Read together, they point to a structural diagnosis: the problem is no longer just output, but conversion.